NEUP is a micro-cap Lynx1 sit, (from $4.75 bid) from late ’25:
26 June 2026 Scancell Holdings plc (AIM: SCLP) (“Scancell” or the “Company”), the developer of active immunotherapies to treat cancer, notes recent press speculation and confirms it is in advanced discussions with Neuphoria Therapeutics Inc. (“Neuphoria”) regarding a potential reverse merger transaction, whereby Scancell would acquire Neuphoria via an all-share transaction.
The potential reverse merger could facilitate a Nasdaq listing for Scancell, which the Company believes could increase its profile with US specialist investors. Concurrently, Scancell is in discussions regarding possible equity and debt financing to support a planned global Phase 3 registrational study for its lead asset, iSCIB1+.
The potential acquisition and associated financing remain subject to inter alia final terms and definitive documentation. There can be no certainty that firm agreement between Scancell and Neuphoria will be reached nor certainty over the quantum and terms of associated financing.
